Inogen (INGN) said Monday it has received the US Food and Drug Administration's clearance for its SIMEOX 200 airway clearance device, which is designed to assist patients with chronic respiratory diseases in managing bronchial drainage.
A limited US launch is planned for next year, the company said.
Shares of Inogen jumped more than 10% in recent premarket activity.
Price: 9.49, Change: +0.91, Percent Change: +10.61
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.